TrialSignal transduction and targeted therapy2025

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.

Yakun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.